Humanigen Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science. | LGC LGC is a life science tools company providing components and solutions for high-growth application areas. | |||
Founding Date | Founding Date 1998 | Founding Date 2002 | Founding Date 2000 | Founding Date 1842 |
Type | Type Public | Type Private | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations San Diego, US HQ Beijing, CN Koblenz, DE Bunkyo City, JP Amsterdam, NL London, GB | Locations Burlingame, US HQ Dublin, IE London, GB Kansas City, US | Locations Teddington, GB HQ São José Dos Campos, BR Sofia, BG Milton, CA Pointe Claire, CA Toronto, CA Beijing, CN see more | |
Employees | Employees 1,49229% increase | Employees 6691% increase | Employees 233% decrease | Employees 1,00814% decrease |
Valuation ($) | Valuation ($) 5.5 b | Valuation ($) N/A | Valuation ($) 4.3 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) £361.7m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) $2.5m (FY, 2022) | Revenue (est.) £142.5m (FY, 2023) |
Cost of goods | Cost of goods £37.3m (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods £88.7m (FY, 2023) |
Gross profit | Gross profit £324.4m (FY, 2022) | Gross profit N/A | Gross profit N/A | Gross profit £53.8m (FY, 2023) |
Net income | Net income (£8.5m) (FY, 2022) | Net income N/A | Net income ($70.7m) (FY, 2022) | Net income £21.3m (FY, 2023) |
Funding | ||||
Total funding raised | Total funding raised $ 78.8m | Total funding raised N/A | Total funding raised $ 131.7m | Total funding raised N/A |